NCT00483132View on ClinicalTrials.gov

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

PHASE3CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

September 30, 1994

Study Completion Date

April 30, 2002

Conditions
Leukemia, Lymphocytic, Acute
Interventions
DRUG

interferon alpha 2a

Trial Locations (1)

49000

INorbert IFRAH, Angers

All Listed Sponsors
lead

French Innovative Leukemia Organisation

OTHER

NCT00483132 - Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III | Biotech Hunter | Biotech Hunter